OS Therapies Incorporated (OSTX) Next Earnings Date & Expected ±12.5% Move

Per the Roarable RQD rating, OSTX carries an RQD score of 42 with a letter grade of D-, labeled "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are: Fundamental Cash Engine at 7/20 (ROIC -35%; FCF yield -21.07%), Whale 13F Flow at 11/20 (institutional accumulation and options positioning), Insider Conviction at 3/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 11/20 (Beta 1.0; sector sensitivity), and Forensic Balance Sheet at 10/20 (Altman Z 2.5; Piotroski F 1/9; Debt/Equity 0.5).

For a prospective investor, the weakest pillar is cash generation: the rating reflects negative return on invested capital and a negative free-cash-flow yield, which indicates the business is consuming rather than producing cash relative to its value. The Insider Conviction pillar, scored lowest at 3/20, signals limited insider-driven confidence signals in the source data. The Whale 13F Flow and Macro Regime pillars sit at the midpoint of their ranges, suggesting that institutional interest and market-beta exposure are not offsetting the fundamental weakness. The Forensic Balance Sheet pillar is also below midpoint, with a low Piotroski F-Score of 1/9. Upside drivers would need to come from outside the current cash-flow profile; the source data does not establish a near-term path to positive free cash flow. Valuation tradeoffs are difficult to assess because P/E, forward P/E, EV/EBITDA, and EPS are not available in source data, so the investor cannot anchor price against earnings. Any evaluation should weigh the negative cash-flow and ROIC readings against the company's reported losses across the periods shown below.

Per the SEC financials, reported revenue is $0.0M in each period shown, and operating and net income are negative in all three. Gross, operating, and net margins are each 0% per the market data. ROIC is -35% per the market data, and the Piotroski F-Score is 1/9 and Altman Z-Score is 2.5 per the Roarable RQD rating. Debt-to-equity is 0.5 per the same rating. Cash and debt balances are N/A in the reported financials.

Per the recent news and catalysts section, the items are:

• A Stock Titan item (YELLOW, MARKET WIRE) citing a figure of 72.7% three-year survival among treated patients versus 45.8% in historical comparisons. The source does not provide study context.
• A StocksToTrade item (RED, RISK WATCH) titled "OSTX Stock Holds Tight Range As Traders Probe Weak Financials."
• Multiple YELLOW MARKET WIRE items covering equity option grants: 200,000 options to the medical chief at a $1.25 exercise price, 900,000 options to the CEO vesting monthly subject to continued employment, and 300,000 options to the CFO at a $1.25 exercise price.

Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links and no proprietary signals.

Per the Butterfly Supply-Chain Graph, there are no upstream or downstream dependencies, no listed sector correlations, and no proprietary signals. Not available in source data for supplier, customer, or bottleneck mapping. Investors should watch whether future filings or sources identify manufacturing, licensing, or clinical-trial partners, as these would be the principal second-order channels for a pharmaceutical preparations issuer, but the current source data does not establish them.

• What are the company's products, approved indications, and revenue sources, given that reported revenue is $0.0M in all periods?
• What is the cash and debt position, given that cash and debt are N/A in the reported financials?
• What is the study context behind the 72.7% versus 45.8% survival figure, and how was it measured?
• What is the planned funding path given negative free cash flow of $-14.2M in FY 2025?
• How do the equity option grants relate to the company's capital and dilution profile?